FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2025/02/079988 [Registered on: 06/02/2025] Trial Registered Prospectively
Last Modified On: 27/04/2026
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Medical Device 
Study Design  Single Arm Study 
Public Title of Study   Cancer Diagnostic probe (CDP) medical device which is used for product validation and safety, sensitivity, and Accuracy concern Cancer Diagnostic Probe (CDP) for the detection of cancer cell during Breast Cancer Surgery - A Multicenter collaborative Observational Project. 
Scientific Title of Study   Assessment of safety, sensitivity, and Accuracy of Cancer Diagnostic Probe (CDP) for the detection of cancer cell during Breast Cancer Surgery - A Multicenter collaborative Pilot Project. 
Trial Acronym  CT-CDP 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Ashutosh Mishra 
Designation  Associate Professor, Room No. 244, Department of Surgical Oncology 
Affiliation  All India Institute of Medical Sciences, New Delhi, India 
Address  All India Institute of Medical Sciences, New Delhi, Ansari Nagar East, New Delhi

South
DELHI
110029
India 
Phone  9650638722  
Fax    
Email  drashutoshmishra11@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Ashutosh Mishra 
Designation  Associate Professor, Room No. 244, Department of Surgical Oncology 
Affiliation  DR BRA-IRCH All India Institute of Medical Sciences, New Delhi, India 
Address  DR BRA-IRCH All India Institute of Medical Sciences, New Delhi, India

South
DELHI
110029
India 
Phone  9650638722  
Fax    
Email  drashutoshmishra11@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Ashutosh Mishra 
Designation  Associate Professor, Room No. 244, Department of Surgical Oncology 
Affiliation  DR BRA-IRCH All India Institute of Medical Sciences, New Delhi, India 
Address  DR BRA-IRCH All India Institute of Medical Sciences, New Delhi, India

South
DELHI
110029
India 
Phone  9650638722  
Fax    
Email  drashutoshmishra11@gmail.com  
 
Source of Monetary or Material Support  
Coosa Technologies Private Limited 
 
Primary Sponsor  
Name  Coosa Technologies Private Limited 
Address  FF, Farm No. 7, Club drive Road, Ghitorni, New Delhi - 110030 
Type of Sponsor  Other [Medical Device Company] 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study
Modification(s)  
No of Sites = 5  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Ashutosh Mishra Associate Professor  All India Institute of Medical Sciences  Department of Surgical Oncologist Room no. 244, East Ansari Nagar, New Delhi
New Delhi
DELHI 
9650638722

drashutoshmishra11@gmail.com 
Dr Ramesh Sarin Senior Consultant   Indraprastha Apollo Hospitals  Sarita Vihar Delhi-Mathura Road New Delhi - 110076 India
New Delhi
DELHI 
9810322237

drmrsrameshsarin@gmail.com 
Dr SVS Deo  Max Super speciality Hospital  No. 1, 2, Press Enclave Road, Mandir Marg, Saket Institutional Area, Saket, New Delhi, 110017, India
New Delhi
DELHI 
9811356594

SVS.Deo@maxhealthcare.com 
Dr Kanchan Kaur Senior Director   Medanta - The Medicity  Sector-38, Gurgaon, Haryana
Gurgaon
HARYANA 
9910388933

kanchan.kaur@medanta.org 
Dr Vivek Gupta Senior Consultant  Pushpawati Singhania Hospital & Research Institute  Phase 2, Sheikh Sarai, Delhi 110017 India
South
DELHI 
9990057517

dr.vivekgupta@hotmail.com 
 
Details of Ethics Committee
Modification(s)  
No of Ethics Committees= 5  
Name of Committee  Approval Status 
Institutional Ethics Committee, Devki Devi Foundation  Approved 
All India Institute of Medical Sciences (AIIMS)  Approved 
Indraprastha Apollo Hospitals  Approved 
Medanta - The Medicity   Approved 
Pushpawati Singhania Hospital & Research Institute  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Approved/Obtained 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: C509||Malignant neoplasm of breast of unspecified site,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Cancer Diagnostic Probe  1. Generic Name :Cancer Diagnostic Probe 2. Brand Name(if registered under the Trade Marks Act, 1999) :Coosa 3. Notified Category :Cancer diagnostic Probe 4. Class of Medical Device :Class C 5. Shelf life :10 years 6. Sterilization:Non-Sterilized 7. Contains Drugs:No 8. Medical Device Grouping Category : Single 9. Grouping Description: NIL 10. Intended Use :Cancer Diagnostic probe can be intended for diagnosis of breast Cancer in all age groups and genders. 11. Product Description: CDP can be used for patients of all ages and genders with breast tumor disease who are candidates for breast-conserving surgery either in adjuvant/nonneoadjuvant cases. The cavity side margins of different histologic subtypes of breast tumors such as invasive ductal carcinoma, invasive lobular carcinoma, malignant phyllodes tumor, atypical ductal hyperplasia, and ductal carcinoma in situ could be checked by CDP intraoperatively. It can also assess the cavity side margins of breast cancer patients who have undergone surgery for first-line treatment, post-neoadjuvant, recurrency, and involved margins. Additionally, CDP can be used to check the intraoperative dissected lymph node status in breast cancer surgery. The CDP device is composed of three main parts: "a disposable sensor; a wireless electrical head probe used by the surgeon; [and] a main control computer system which receives the signals from the head probe. It electrochemically measures the hypoxia glycolysis metabolism in real-time "in pre-cancerous and cancerous lesions in cavity side margins". It measures the release of H2O2 from cancer or atypical cells by the reverse Warburg effect. 12. Material of Construction: Li-Ion battery, Electrodes, Display panel and bluetooth software 13. Dimension: 14. Storage Condition: Room Temperature 14. Pack Size: Single Unit 15. Accessory: NIL 16. Model No. :SG 1 - Portable Cancer Diagnostic Probe 7.4 V 17. Equivalence to predicte device :No 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  65.00 Year(s)
Gender  Both 
Details  The following inclusion criteria will be considered for the study CDP can be used for patients of all ages and genders with breast tumor disease who are candidates for breast conserving surgery in adjuvant non neoadjuvant cases.
 
 
ExclusionCriteria 
Details  Patients with the following will be excluded from the study
1. Patients with non palpable tumor
2. Patients exhibiting post NACT complete response
All patients diagnosed with breast cancer which were candidates for breast conserving surgery. All the patients will be informed about the process and sign the consent before the surgery. The patient gender, age, and surgical history, and adjuvant or neoadjuvant chemotherapy are not effective parameters for the patient recruitment. 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
We will provide the primary outcomes data In process Clinical trial observations.  Secondary outcome data will start on after 6 Weeks. 
 
Secondary Outcome  
Outcome  TimePoints 
To observe the results after the pathology findings.  based on observational study data which comes after 14 weeks. 
 
Target Sample Size   Total Sample Size="50"
Sample Size from India="50" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   15/03/2025 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="0"
Months="3"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  
Not Applicable 
Recruitment Status of Trial (India)  Open to Recruitment 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - YES
  1. What data in particular will be shared?
    Response - All of the individual participant data collected during the trial, after de-identification.

  2. What additional supporting information will be shared?
    Response -  Study Protocol
    Response -  Statistical Analysis Plan
    Response - Informed Consent Form
    Response - Clinical Study Report
    Response -  Analytic Code

  3. Who will be able to view these files?
    Response - Researchers who provide a methodologically sound proposal.

  4. For what types of analyses will this data be available?
    Response - For individual participant data meta-analysis.

  5. By what mechanism will data be made available?
    Response - Proposals should be directed to [ravimittal@coosa.in].

  6. For how long will this data be available start date provided 01-07-2025 and end date provided 30-06-2028?
    Response - Beginning 9 months and ending 36 months following article publication.

  7. Any URL or additional information regarding plan/policy for sharing IPD? 
    Additional Information - NIL
Brief Summary
Modification(s)  
Full Title of the Study: Assessment of safety, sensitivity, and Accuracy of Cancer Diagnostic Probe (CDP) for the detection of cancer cell during Breast Cancer Surgery - A Multicenter collaborative Pilot Project.

Objectives of the study :        

·        Primary Objectives:

1.      To assess the safety, sensitivity, and accuracy of Cancer Diagnostic Probe (CDP) for breast cancer detection during Breast cancer surgery. 

·        Secondary Objectives:

1.   To detect cancer cell at the margin of post lumpectomy cavity wall

2.   To compare the sensitivity of CDP and Frozen section in breast cancer surgery

3.  To compare the sensitivity of CDP and Frozen section in detecting Cancer cells in Sentinel Lymph Node.

Justification for conduct of this study

      Breast cancer (BC) is the most prevalent malignant solid tumor among women worldwide, and Breast Conserving Surgery (BCS) has been proven as the best surgery method for early-stage BC patients in clinical studies. Remained positive margins is still a moot point with drastic impact on risk of cancer recurrence. Residue of tumor cells in cavity side may induce dangerous challenge as they are in interaction with accumulated cytokines (in surgical bed fluid).  Therefore, it is imperative to develop effective strategies to minimize involved margins and ensure optimal results for patients.  Up to 20 % of the margins may remain positive despite utilizing conventional intra-operative methods. In addition, the frozen section is a time-consuming, expensive and labor-intensive process, adding the risk of false negatives (6-20%) owing to technical limitations such as incomplete fixation of pathology samples. Bioelectronic science has emerged as a novel strategy in cancer research, allowing discrimination between cancerous and non-cancerous cells and tissues, broadening the horizon of cancer research. A recently developed technique, the Cancer diagnostic probe (CDP) (granted USA patents: US 11,179,076 B2, US 10,786,188 B1, US 11,179,077 B2, US 11,181,499 B2, US 11,806,140 B2), has been known as another complementary electrical method, which shed new lights in real-time diagnosing the presence of pre-cancerous and cancerous cells in cavity margins of breast tumors via the assistance of electrical probing on biochemical metabolism of the live cells in the margins.This highlights the impact of CDP as an innovative intraoperative technique to evaluate cavity side margins effectively.

Methodology:

Study site and Design:  

·        This is a prospective pilot study, and the study will be carried out in the Department of Surgical Oncology, All India Institute of Medical Sciences, New Delhi, India.

·        A total of 50 patients confirming the diagnosis of breast cancer.

 Patient Recruitment and Sample Collection:

·        Ethical approval for the study will be taken from the Institute Ethics Committee, All India Institute of Medical Sciences (AIIMS), New Delhi, India.

·        Each patient will be enrolled after approval from EIC with their written informed consent.

·        For the study, prospectively selected n=50 patients with tumor will be recruited, irrespective of their treatment status. CDP will be applied on tumor and normal cells during surgery (MRM/ Breast Conserving Surgery). Hence the tumor cell, normal cells, cavity margins and sentinel LN will be assessed by CDP. The results will be observed accordingly and further correlated with histopathology report.    

Inclusion and Exclusion Criteria:

The following inclusion criteria will be considered for the study 

CDP can be used for patients of all ages and genders with breast tumor disease who are candidates for breast-conserving surgery in adjuvant/non-neoadjuvant cases.

    

Patients with the following will be excluded from the study:  

1. Patients with non-palpable tumor

2. Patients exhibiting post-NACT complete response

All patients diagnosed with breast cancer, which were candidates for breast-conserving surgery. All the patients will be informed about the process and sign the consent before the surgery. The patient’s gender, age, and surgical history, and adjuvant or neoadjuvant chemotherapy are not effective parameters for the patient’s recruitment.

The workflow of the proposed study is as follows

This is a multicenter pilot study for evaluating the safety, sensitivity, and Accuracy of a Cancer Diagnostic Probe (CDP) for the detection of cancer cells in-vivo during Breast Cancer Surgery and subsequently, results obtained by the CDP probe will be compared with gold standard histopathology of the same cavity lesion recorded by CDP. During breast-conserving surgery, the surgeon will apply the CDP on cavity side margins (CDP electrodes should be inserted up to 4 mm) after resection of the tumor (the resected tumor will be sent for a frozen section and then permanent pathology (pathological evaluation on tumor side margins)). Surgeons will not be biased toward the CDP scoring results. So, all negatively and positively scored lesions will be re-excised for pathological evaluation. The size of each excised lesion will be about 1×1×1 cm3. These samples are called as “CDP Samples”. The required time for checking all of the margins by CDP is about 10 min. 

CDP Samples will be sent for permanent pathology to be evaluated pathologically as the gold standard. At this stage, the pathologist must be blinded to the CDP results. In this manner, we have no bias during the trial and the score of CDP does not affect the decision of the surgeon and pathologist while all of the data will be compared with an accepted gold standard. Independently the tumor (the resected tumor) will be sent for a frozen section and then permanent pathology (pathological evaluation on tumor side margins). Finally, after the collection of all lesions in fixed block samples (cavity side lesions recorded by CDP), the lesions will be sent for H&E slide sectioning, and independent and blind pathologists will evaluate and declare their diagnosis on the cavity lesions. Finally, the epidemiologist of the project will integrate all the data and report two tables. The first matching table of CDP scores by H&E of cavity margins (as sensitivity and accuracy), the second comparative table between CDP score, the frozen score of the tumor side and the permanent score of the tumor side all with the permanent score of the cavity side (gold merit) in second table the sensitivity and accuracy of frozen and permanent of tumor side will also be compared with the pathologic state of cavity side margins. Also, the cross table and ROC curve will be presented to compare the results.


 
Close